Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05109728 · ClinicalTrials.gov registry record · Phase 1
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
A Phase 1 study of Glioblastoma, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
- 14
- Study locations
NCT05109728 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 65 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (40% lower). The trial reports 14 study locations across 6 states.
The verdict
NCT05109728, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
- 14
- Study locations
Study Summary
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Conditions Studied
Interventions
- DRUG [177Lu]Lu-DOTA-TATE
- DRUG [68Ga]Ga-DOTA-TATE
- OTHER Temozolomide
- OTHER Radiotherapy
Study Locations (14)
Other
- Novartis Investigative Site - Bron
- Novartis Investigative Site - Marseille
- Novartis Investigative Site - Porto
- Novartis Investigative Site - Barcelona
- Novartis Investigative Site - Barcelona
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Lausanne
- Novartis Investigative Site - Zurich
New York
- Col Uni Med Center New York Presby - New York
Pennsylvania
- University of Pittsburgh - Pittsburgh
Texas
- MD Anderson Cancer Center Uni of Te - Houston
Wisconsin
- University of Wisconsin School of Medicine and Public Health - Madison
Andalusia
- Novartis Investigative Site - Granada
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2022-05-10 |
| Est. Completion | 2027-07-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05109728
The ClinicalTrials.gov registry entry for NCT05109728 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (40% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 4 interventions - of which [177Lu]Lu-DOTA-TATE is the first listed.
NCT05109728 reports 14 study locations spanning 6 distinct geographic areas - top geographies include Other, New York, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05109728 about?
NCT05109728 is a clinical study titled "A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.". A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
What is the current status of trial NCT05109728?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2022-05-10. Estimated completion is 2027-07-31.
What conditions does trial NCT05109728 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT05109728?
The interventions under investigation include: [177Lu]Lu-DOTA-TATE (DRUG), [68Ga]Ga-DOTA-TATE (DRUG), Temozolomide (OTHER), Radiotherapy (OTHER).
Who is sponsoring clinical trial NCT05109728?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05109728 being conducted?
This trial has 14 study locations across New York, Pennsylvania, Texas, Wisconsin, Andalusia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.